FGFR2 amplification in colorectal adenocarcinoma

Jamal H. Carter, Catherine E. Cottrell, Samantha N. McNulty, Katinka A. Vigh-Conrad, Stephen Lamp, Jonathan W. Heusel, Eric J. Duncavage

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

FGFR2 is recurrently amplified in 5% of gastric cancers and 1%-4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKIs), such as AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell line, NCI-H716. The efficacy of these inhibitors is currently under investigation in clinical trials for breast and gastric cancer. Thus, better characterizing colorectal tumors for FGFR2 amplification could identify a subset of patients who may benefit from FGFR TKI therapies. Here, we describe a novel FGFR2 amplification identified by clinical next-generation sequencing in a primary colorectal cancer. Further characterization of the tumor by immunohistochemistry showed neuroendocrine differentiation, similar to the reported properties of the NCI-H716 cell line. These findings demonstrate that the spectrum of potentially clinically actionable mutations detected by targeted clinical sequencing panels is not limited to only single-nucleotide polymorphisms and insertions/deletions but also to copy-number alterations.

Original languageEnglish (US)
JournalCold Spring Harbor molecular case studies
Volume3
Issue number6
DOIs
StatePublished - Nov 1 2017
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Adenocarcinoma
Protein-Tyrosine Kinases
Stomach Neoplasms
Breast Neoplasms
Cell Line
Single Nucleotide Polymorphism
Immunohistochemistry
Clinical Trials
Mutation
Neoplasms
Therapeutics
AZD4547
In Vitro Techniques

Keywords

  • colon cancer
  • neoplasm of the gastrointestinal tract

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Carter, J. H., Cottrell, C. E., McNulty, S. N., Vigh-Conrad, K. A., Lamp, S., Heusel, J. W., & Duncavage, E. J. (2017). FGFR2 amplification in colorectal adenocarcinoma. Cold Spring Harbor molecular case studies, 3(6). https://doi.org/10.1101/mcs.a001495

FGFR2 amplification in colorectal adenocarcinoma. / Carter, Jamal H.; Cottrell, Catherine E.; McNulty, Samantha N.; Vigh-Conrad, Katinka A.; Lamp, Stephen; Heusel, Jonathan W.; Duncavage, Eric J.

In: Cold Spring Harbor molecular case studies, Vol. 3, No. 6, 01.11.2017.

Research output: Contribution to journalArticle

Carter, JH, Cottrell, CE, McNulty, SN, Vigh-Conrad, KA, Lamp, S, Heusel, JW & Duncavage, EJ 2017, 'FGFR2 amplification in colorectal adenocarcinoma', Cold Spring Harbor molecular case studies, vol. 3, no. 6. https://doi.org/10.1101/mcs.a001495
Carter JH, Cottrell CE, McNulty SN, Vigh-Conrad KA, Lamp S, Heusel JW et al. FGFR2 amplification in colorectal adenocarcinoma. Cold Spring Harbor molecular case studies. 2017 Nov 1;3(6). https://doi.org/10.1101/mcs.a001495
Carter, Jamal H. ; Cottrell, Catherine E. ; McNulty, Samantha N. ; Vigh-Conrad, Katinka A. ; Lamp, Stephen ; Heusel, Jonathan W. ; Duncavage, Eric J. / FGFR2 amplification in colorectal adenocarcinoma. In: Cold Spring Harbor molecular case studies. 2017 ; Vol. 3, No. 6.
@article{4ab8cb6ec6314f6f8c02b70945c3a379,
title = "FGFR2 amplification in colorectal adenocarcinoma",
abstract = "FGFR2 is recurrently amplified in 5{\%} of gastric cancers and 1{\%}-4{\%} of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKIs), such as AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell line, NCI-H716. The efficacy of these inhibitors is currently under investigation in clinical trials for breast and gastric cancer. Thus, better characterizing colorectal tumors for FGFR2 amplification could identify a subset of patients who may benefit from FGFR TKI therapies. Here, we describe a novel FGFR2 amplification identified by clinical next-generation sequencing in a primary colorectal cancer. Further characterization of the tumor by immunohistochemistry showed neuroendocrine differentiation, similar to the reported properties of the NCI-H716 cell line. These findings demonstrate that the spectrum of potentially clinically actionable mutations detected by targeted clinical sequencing panels is not limited to only single-nucleotide polymorphisms and insertions/deletions but also to copy-number alterations.",
keywords = "colon cancer, neoplasm of the gastrointestinal tract",
author = "Carter, {Jamal H.} and Cottrell, {Catherine E.} and McNulty, {Samantha N.} and Vigh-Conrad, {Katinka A.} and Stephen Lamp and Heusel, {Jonathan W.} and Duncavage, {Eric J.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1101/mcs.a001495",
language = "English (US)",
volume = "3",
journal = "Cold Spring Harbor molecular case studies",
issn = "2373-2873",
publisher = "Cold Spring Harbor Laboratory Press",
number = "6",

}

TY - JOUR

T1 - FGFR2 amplification in colorectal adenocarcinoma

AU - Carter, Jamal H.

AU - Cottrell, Catherine E.

AU - McNulty, Samantha N.

AU - Vigh-Conrad, Katinka A.

AU - Lamp, Stephen

AU - Heusel, Jonathan W.

AU - Duncavage, Eric J.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - FGFR2 is recurrently amplified in 5% of gastric cancers and 1%-4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKIs), such as AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell line, NCI-H716. The efficacy of these inhibitors is currently under investigation in clinical trials for breast and gastric cancer. Thus, better characterizing colorectal tumors for FGFR2 amplification could identify a subset of patients who may benefit from FGFR TKI therapies. Here, we describe a novel FGFR2 amplification identified by clinical next-generation sequencing in a primary colorectal cancer. Further characterization of the tumor by immunohistochemistry showed neuroendocrine differentiation, similar to the reported properties of the NCI-H716 cell line. These findings demonstrate that the spectrum of potentially clinically actionable mutations detected by targeted clinical sequencing panels is not limited to only single-nucleotide polymorphisms and insertions/deletions but also to copy-number alterations.

AB - FGFR2 is recurrently amplified in 5% of gastric cancers and 1%-4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKIs), such as AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell line, NCI-H716. The efficacy of these inhibitors is currently under investigation in clinical trials for breast and gastric cancer. Thus, better characterizing colorectal tumors for FGFR2 amplification could identify a subset of patients who may benefit from FGFR TKI therapies. Here, we describe a novel FGFR2 amplification identified by clinical next-generation sequencing in a primary colorectal cancer. Further characterization of the tumor by immunohistochemistry showed neuroendocrine differentiation, similar to the reported properties of the NCI-H716 cell line. These findings demonstrate that the spectrum of potentially clinically actionable mutations detected by targeted clinical sequencing panels is not limited to only single-nucleotide polymorphisms and insertions/deletions but also to copy-number alterations.

KW - colon cancer

KW - neoplasm of the gastrointestinal tract

UR - http://www.scopus.com/inward/record.url?scp=85039775984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039775984&partnerID=8YFLogxK

U2 - 10.1101/mcs.a001495

DO - 10.1101/mcs.a001495

M3 - Article

VL - 3

JO - Cold Spring Harbor molecular case studies

JF - Cold Spring Harbor molecular case studies

SN - 2373-2873

IS - 6

ER -